Clobexpro

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clobexpro

Property Description
Active Ingredient Clobetasol Propionate
Form Topical preparations (Lotion, Shampoo, Spray, Cream, Ointment)
Pharmacological Class Topical Corticosteroid (Super-High Potency)
Common Use Control of severe inflammatory and pruritic skin manifestations
Origin Synthetic (Fluorinated Corticosteroid)

Clobexpro: Identity and Pharmacological Classification

Clobexpro is a highly potent, prescription-only medication defined by its active chemical substance, clobetasol propionate. This substance classifies the drug as a Topical Corticosteroid and a glucocorticoid, belonging to the strongest available strength category, often termed super-high potency (Group I). Clobetasol Propionate formulations are categorized in this highest potency rating, a classification supported by pharmacological studies on its vasoconstrictor assay activity. This high potency is a key differentiating factor, making it suitable for short-term management of acute inflammatory flare-ups where milder agents are ineffective.

Composition, Forms, and Synthetic Origin

The chemical basis of Clobexpro is its single-ingredient active compound, clobetasol propionate, which is a synthetic fluorinated corticosteroid derivative. The medication is exclusively formulated for topical application and is supplied in multiple specialized dosage forms, including a liquid lotion, a liquid shampoo specifically designed for the scalp, a targeted spray, and emollient forms like cream and ointment. This variety of pharmaceutical preparations allows for the precise application of the potent ingredient to different anatomical areas, such as the hair-bearing skin or thicker plaques.

General Purpose: Anti-Inflammatory and Antipruritic Action

The overall therapeutic objective of Clobexpro is to provide rapid and effective control over severe, localized skin inflammation. Its primary action is rooted in its anti-inflammatory and vasoconstrictive properties. Topical agents like clobetasol propionate are clinically recognized for their ability to suppress the release of various chemicals that promote swelling and itching. This potent mechanism is specifically intended to quickly mitigate intense inflammatory manifestations and associated severe pruritic manifestations (itching) that arise from various corticosteroid-responsive dermatoses.

Regulatory References

  1. FDA Labeling (Clobetasol Propionate)
  2. Topical Corticosteroids (NIH/NCBI)

What side effects are possible with Clobexpro?

Possible Side Effects and Safety Information

Clobexpro is a highly potent corticosteroid, and its safety profile is defined by potential systemic absorption and local skin reactions, as documented by official regulatory bodies.

Adverse Reactions

The adverse reactions associated with this medicine are classified by frequency based on clinical trial data:

Classification Adverse Reaction
Common Burning/stinging, pruritus (itching)
Uncommon Skin atrophy (thinning), telangiectasia (spider veins), ecchymosis (bruising), Hypothalamic-Pituitary-Adrenal (HPA) axis suppression

Serious systemic adverse reactions that may occur due to sufficient absorption through the skin include HPA axis suppression, which is a potentially life-threatening endocrine disorder. Other documented serious effects include Cushing's syndrome and hyperglycemia.

Safety Restrictions and Considerations

Official regulatory information outlines specific restrictions and considerations for use:

  • Contraindicated Areas: The medicine is explicitly restricted from use on the face, groin, or axillae (armpits) due to the higher risk of systemic absorption and local side effects like skin atrophy.
  • Ophthalmic Risk: Contact with the eyes should be avoided as it may lead to cataracts or glaucoma.
  • Pediatric Population: Children are considered more susceptible to systemic toxicity, including HPA axis suppression and Cushing's syndrome, because their skin surface area is larger relative to their body mass.
  • Exposure Pattern: The risk of both local and systemic adverse effects increases with longer treatment durations or when large skin surface areas are treated.

Overdose and Emergency Response

Overdose and when to Seek Help

The official overdose profile for Clobexpro is defined by the consequences of systemic absorption of the super-high potency corticosteroid following excessive or prolonged topical use.


Field Official Regulatory Statements
Documented Overdose Presentations Overdose manifestations are primarily caused by Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, leading to signs consistent with Cushing’s syndrome and potential Glucocorticosteroid insufficiency. Metabolic effects such as hyperglycemia and glucosuria are also documented.
Exposure Risk Systemic toxicity is associated with application amounts exceeding the label-recommended maximum (e.g., typically 50 g per week or equivalent based on formulation).
When Immediate Medical Help Is Required Urgent medical attention is required if there is documented evidence of adrenal suppression or if severe clinical signs of steroid withdrawal occur. These scenarios may necessitate the administration of supplemental systemic corticosteroids.
Monitoring and Management Management procedures include periodic evaluation for HPA axis suppression using diagnostic tools like the ACTH stimulation test. Official actions involve withdrawal of the drug or substitution with a less potent alternative. No specific antidote is known.

Population-Specific Considerations

  • Pediatric patients are at an increased susceptibility to systemic toxicity due to a higher skin surface area-to-body mass ratio.
  • Documented manifestations unique to children include linear growth retardation, delayed weight gain, and signs of intracranial hypertension (e.g., bulging fontanelles).

Therapeutic Uses of Clobexpro

Quick Facts on Therapeutic Domains

  • Scalp Psoriasis: A topical treatment option for adults managing moderate to severe forms of scalp psoriasis.
  • Inflammatory Manifestations: May assist in addressing the inflammatory and pruritic (itchy) signs associated with the condition.

Clobexpro: Main Uses and Benefits

Clobexpro, which contains clobetasol propionate, is indicated for adults to manage moderate to severe forms of scalp psoriasis.

The core benefit of using this prescribed topical medication is to provide relief from the common, visible signs and discomfort associated with the condition. It is used in the clinical setting to address the inflammatory and pruritic manifestations of scalp psoriasis, helping to soothe redness, irritation, and discomfort.

This medication is a component of a comprehensive treatment plan for adults with this specific skin condition. The use of this topical agent is confined to the scalp area, as determined by a healthcare professional. Clobexpro works within the approved therapeutic domain to manage the signs and symptoms of the condition.

The medication is designed to support the overall management of the condition's visible presentation, aligning with established medical protocols for corticosteroid-responsive dermatoses.

Eligibility and Restrictions for Use

Clobexpro (Clobetasol Propionate) eligibility is strictly governed by official regulatory criteria that identify specific populations who must not use the medication due to documented risks.

Contraindicated and Prohibited Use

Category Eligibility Rule
Hypersensitivity Contraindicated in patients with a history of allergy to clobetasol propionate or any component of the formulation.
Dermatoses Prohibited Prohibited for treating conditions like rosacea, perioral dermatitis, acne vulgaris, and primary skin infections.
Age Exclusion Contraindicated in children under one year of age.

Age and Restricted Populations

Use is not recommended in most pediatric patients. Safety and effectiveness are not established for children typically under 12 years of age, and the risk of systemic toxicity is high. In older adults, some clinical studies have lacked sufficient subject numbers to determine differing responses.

Use is strictly restricted to specific body areas; it is prohibited for application on the face, groin, and axillae (underarms). For pregnancy and lactation, official guidance recommends use only if the potential benefit justifies the potential risk to the fetus or infant. Patients with significant hepatic or renal impairment require caution due to the possibility of delayed systemic drug clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clobexpro (Clobetasol Propionate) interactions are primarily defined by the risk of increased systemic exposure and additive effects, as documented in regulatory information. All interactions listed below are based on official prescribing information.

Documented Pharmacokinetic Interactions

Classification Type Interacting Substance/Class
Metabolic Pathway Inhibitor Strong CYP3A4 inhibitors (e.g., Ritonavir, Itraconazole)

Co-administration with strong CYP3A4 inhibitors can inhibit the metabolism of Clobetasol Propionate, which results in increased systemic exposure of the corticosteroid. This is a clinically significant interaction noted in official labeling.

Pharmacodynamic and Restriction Rules

Restriction Type Interacting Substance/Condition
Contraindicated Combination Other topical corticosteroid-containing products
Additive Systemic Risk Immunosuppressants (e.g., Methotrexate, Mycophenolate Mofetil)
Co-Use Restriction Untreated cutaneous infections

Combining Clobexpro with other topical corticosteroid-containing products is explicitly advised against due to the risk of additive systemic effects such as HPA axis suppression. Use with immunosuppressants can lead to an increased risk of serious systemic undesirable effects, including systemic immunosuppression. No specific timing separation rules are required for co-administered oral medicines.

Population-Specific Notes

Pediatric patients are noted to be at a higher risk for systemic toxicity due to proportionally larger systemic absorption. Individuals with hepatic impairment are also identified as having an increased chance of systemic side effects due to impaired drug clearance.

Mechanism of Action

Gene Expression and Receptor-Mediated Signaling

Clobexpro (clobetasol propionate) is a synthetic corticosteroid that acts within domains involving receptor-mediated signaling. The compound readily diffuses across cell membranes and binds to cytosolic glucocorticoid receptors. This ligand-receptor complex translocates to the nucleus, where it engages with DNA, regulating the transcription of specific genes. This action alters the expression of numerous proteins involved in inflammatory signaling pathways.

Regulation of Inflammatory Mediator Pathways

Key biological cascades are modified through the induction of lipocortins (annexin A1) synthesis. Lipocortins inhibit the enzyme phospholipase A2. This enzymatic inhibition is a critical step that prevents the liberation of arachidonic acid from cell membrane phospholipids, subsequently suppressing the biosynthesis of potent inflammatory mediators, specifically prostaglandins and leukotrienes.

Local Microcirculation and Vascular Modulation

Systemic physiological consequences include an immediate local vasoconstrictive effect. This mechanism acts to restrict blood flow in the treated tissue. The resulting physiological modulation includes a reduction in capillary permeability and decreased migration of immune cells to the application site, which affects localized fluid balance.

Dosage and Administration Information

Clobexpro is a super-high potency topical corticosteroid administered exclusively via the cutaneous route for external use. Its application is prohibited for oral, ophthalmic (eye), or intravaginal purposes. The therapeutic protocol is strictly time- and quantity-limited to control total exposure to the potent active ingredient.

Usage Principle Administration Guideline
Maximum Weekly Dose The total quantity applied must not exceed 50 grams (or 50 mL / 1.75 fl. oz.) per week across all formulations.
Duration of Use Treatment is designated as short-term only, commonly limited to two consecutive weeks for most forms, or up to four consecutive weeks for the shampoo formulation or specific plaque psoriasis lesions.
Frequency Most creams, lotions, and ointments are typically applied twice daily. The shampoo formulation is applied once daily to the affected area of the dry scalp.
Anatomical Restrictions The medicine must not be applied to the face, groin, or underarms (axillae).
Pediatric Use Use is frequently restricted, and the product is not generally recommended for children under the age of 12 or 18, depending on the specific formulation.

For the shampoo form, application involves applying the dose to the dry scalp, leaving it in place for 15 minutes, and then rinsing thoroughly. Use is structured to be discontinued promptly once control of the condition is achieved, rather than following a continuous course. These guidelines define the standardized approach to utilizing this potent medication.

Recent Clinical Evidence

Evidence for Use in Psoriasis and Severe Dermatoses

Clobexpro's research base primarily consists of short-term randomized controlled trials (RCTs) that examined its application for moderate to severe plaque psoriasis and other corticosteroid-responsive conditions. These studies were applied in research contexts involving conditions characterized by fluctuating manifestations.

Researchers typically used a double-blind, vehicle-controlled (placebo) design to monitor manifestations. Research examined outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. Standardized scales, like the Physician's Global Assessment (PGA), were employed to monitor the overall presentation of the condition, along with measurements of erythema, scaling, and pruritus.

Comparison of Formulations and Potency Studies

The active ingredient was studied for its use across various topical preparations, including liquid shampoo, lotion, spray, cream, and ointment. Regulatory bodies rely on non-clinical pharmacodynamic studies, like the vasoconstrictor assay, which research describes for the purposes of classifying Clobetasol Propionate as a super-high potency topical corticosteroid.

Comparative evidence is lacking for the different Clobetasol Propionate formulations directly against each other in clinical trials, as the regulatory focus is typically on comparing each formulation to an inactive vehicle. The evidence quality varies across studies when looking at comparisons with other active agents.

Research Gaps and Areas of Uncertainty

Research found that follow-up durations were limited in the initial studies, leaving long-term effects not fully established. Additionally, the data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes in pediatric subjects, and generally, children under 12 years of age have not been adequately evaluated in the pivotal efficacy trials. This means subgroup findings are uncertain and the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Clobexpro (FAQ)


Q: Is it normal to feel a mild sting when first applying Clobexpro?

According to official product information, burning or stinging at the application site is listed as one of the more common adverse reactions associated with the use of topical clobetasol propionate. This sensation is described in official safety data as a common adverse reaction noted during clinical trials.


Q: Is Clobexpro the same as other steroid creams I've used before?

Clobexpro contains the active ingredient clobetasol propionate, which is classified by regulatory agencies as a super-high potency topical corticosteroid. This classification places it in the strongest potency class available for topical steroids. This high potency classification differentiates it from topical corticosteroids classified in lower potency groups.


Q: What is the 'rebound effect' people mention when stopping a topical steroid?

Official information describes the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. This clinical concept is linked to the drug's potential to suppress the hypothalamic-pituitary-adrenal (HPA) axis, which manages the body's natural steroid production. For this reason, official use guidelines state that treatment should be discontinued promptly once control of the condition is achieved.


Q: Do children or elderly people use Clobexpro differently?

Use is generally not recommended in children under 12 years of age because regulatory documents indicate they have an increased susceptibility to systemic toxicity. This includes a higher risk of adverse effects like HPA axis suppression and Cushing’s syndrome. Safety and effectiveness are generally not established for most pediatric populations, and clinical studies primarily evaluated adult subjects.


Q: Can I use Clobexpro if I'm pregnant or breastfeeding?

Official labeling formerly categorized the drug as Pregnancy Category C, meaning that the risk cannot be ruled out. Regulatory documents state that use is recommended only if the potential benefit justifies the potential risk to the fetus or infant. Guidance advises that if the medication is used, it should be applied to the smallest area of skin possible and for the shortest duration.


Q: Can I use other lotions or moisturizers with Clobexpro?

Official prescribing information advises against the co-administration of other topical corticosteroid-containing products due to the risk of additive systemic effects. While official documents do not typically address non-medicated moisturizers, some product labels have noted the allowance for the use of non-medicated shampoos alongside the scalp formulation.


Q: Is Clobexpro known to cause headaches or tiredness?

Official safety data lists headache as a common adverse reaction, reported in 1% to 10% of users during clinical trials. Unusual tiredness or weakness has also been reported and may be described as a sign of systemic effects resulting from the drug's absorption, such as HPA axis suppression.


Q: Can Clobexpro interact with herbal supplements like St. John's wort?

Clobetasol propionate is primarily metabolized by the CYP3A4 enzyme in the body. Co-administration with substances, including certain herbal supplements, that inhibit or induce this enzyme’s activity may lead to altered systemic exposure of the corticosteroid. Official interaction information focuses on the mechanism of action, specifically the CYP3A4 enzyme, rather than providing an exhaustive list of every potentially interacting substance.


Q: Why do some people need to cover the area after using Clobexpro?

Official guidelines describe that the treated area should not be covered, bandaged, or wrapped unless specifically directed by a healthcare provider. Covering the area, known as occlusion, is noted in regulatory information to increase the risk of both local adverse reactions and systemic absorption of the potent medicine.


Q: Is Clobexpro available over the counter, or is it prescription-only?

Clobetasol propionate is classified by regulatory bodies as a prescription-only medication in all its approved topical formulations. It is not available for purchase over the counter.


Q: Are there any specific foods or supplements to avoid while using Clobexpro?

No specific interactions with food or common beverages are routinely noted in regulatory documents. As a topical application, systemic interactions with diet are not typically a concern addressed in the product labeling.


Q: Does Clobexpro cause permanent skin color changes?

Changes in skin coloring, specifically hypopigmentation (lightening of the skin), have been reported in safety data. These skin color changes are classified as an adverse reaction, with official data noting that the long-term nature of such changes is not always fully established or is listed as 'incidence not known'.


Q: What are the major differences between the Clobexpro lotion and the foam?

Clobetasol propionate is supplied in multiple formulations (lotion, foam, spray, cream, ointment) to facilitate application to different affected areas, such as the hair-bearing scalp or drier plaques. The official information notes that the various vehicles may exhibit small differences in percutaneous absorption and vasoconstrictor potency.


Q: Can sun exposure affect how Clobexpro works?

Studies have examined the use of clobetasol propionate in combination with controlled light exposure, such as UVB light therapy, for certain conditions. However, general information regarding the effects of casual, uncontrolled sun exposure on the drug's mechanism or efficacy is not routinely noted in official product documents.


Q: Does alcohol or smoking have an interaction with Clobexpro?

No specific interactions with alcohol have been routinely noted in regulatory documents. Furthermore, information regarding interactions with smoking is not generally present in drug labeling.


Q: Can Clobexpro be used for poison ivy or bug bites?

Clobetasol propionate formulations are officially indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as moderate to severe plaque psoriasis. No explicit indication for use on common, minor conditions like poison ivy or general insect bites is included in the labeling.


Q: Does Clobexpro expire, and can I still use it past the expiration date?

Regulatory authorities establish expiration dates based on stability testing to ensure the product meets standards of strength and purity throughout its shelf life. Official guidance warns that using a medication past its expiration date may result in the product having lower strength or potentially yielding toxic compounds.

How should Clobexpro be stored and disposed of?

Storage and Disposal of Clobetasol Propionate (Clobex)

Clobetasol Propionate formulations must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from freezing, and specific forms, like the spray, must not be refrigerated. The container must be kept tightly closed to maintain product stability.

Since certain preparations, such as the spray and foam, are flammable, they must be stored and handled away from heat or open flame. All forms of this medication must be stored securely out of the reach of children. Unused or expired Clobetasol Propionate should be disposed of according to local regulatory guidelines, often involving disposal at an approved waste disposal plant to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clobexpro found in:

A-Z Index: